BRIEF-Nighthawk Biosciences Appoints Stephan Kutzer As Interim Chief Executive Officer Of Scorpion Biological Services · 06/13 12:25
NHWK: Name Change and New Facility
By John Vandermosten, CFA NYSE:NHWK READ THE FULL NHWK RESEARCH REPORT The recently renamed NightHawk Biosciences, Inc. (NYSE:NHWK) reported first quarter 2022 results on May 16, 2022 and filed its Form 10-Q with the SEC. It has been a whirlwind year for t...
Zacks Small Cap Research · 05/18 16:48
The Daily Biotech Pulse: Pfizer/BioNTech's COVID-19 Booster For Kids, Moderna Starts First African Trial Of mRNA HIV Vaccine, Tonix Extends COVID-19 Antiviral Research Pact
Here's a roundup of top developments in the biotech space over the last 24 hours.
Benzinga · 05/18 14:15
NightHawk Biosciences GAAP EPS of -$0.32 beats by $0.17
NightHawk Biosciences press release (NYSE:NHWK): Q1 GAAP EPS of -$0.32 beats by $0.17. Recognized $0.2 million of grant revenue for qualified expenditures under the CPRIT grant for the quarter ended
Seekingalpha · 05/16 20:49
NightHawk Biosciences to Present at the 4th Annual Treg Directed Therapies Summit on PTX-35
DURHAM, N.C., May 10, 2022 (GLOBE NEWSWIRE) -- NightHawk Biosciences (NYSE American: NHWK), a fully integrated biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system, today announced that Matthew Seavey, Ph.D...
GlobeNewswire · 05/10 12:00
Morrisville drugmaker scores $6M deal with Canada for anthrax treatment
The Canadian contract follows a recent deal with the U.S. government worth up to $81 million for the anthrax treatment.
American City Business Journals · 04/27 19:15
Heat Biologics (NightHawk Biosciences) Announces that its Elusys Therapeutics Subsidiary has Executed a Contract to Deliver ANTHIM® to the Canadian Government
New contract marks the first international sale of ANTHIM® and follows recent acquisition of Elusys by NightHawkDURHAM, N.C., April 27, 2022 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. (NYSE American: HTBX) (to be renamed “NightHawk Biosciences”), a fully int...
GlobeNewswire · 04/27 12:00
Morrisville drugmaker changing name, subsidiary plans $650M manufacturing facility in Kansas
A public company headquartered in Morrisville is preparing to change its name as one of its subsidiaries plans a 500-job manufacturing facility for biodefense in Kansas.
American City Business Journals · 04/21 12:01
Heat Biologics to rebrand as NightHawk Biosciences from next month
The clinical-stage biotech, Heat Biologics (NYSE:HTBX), announced on Tuesday that it would change its name to NightHawk Biosciences effective May 03. The name change will coincide with a change in
Seekingalpha · 04/19 15:49
Heat Biologics Announces Planned Name Change To NightHawk Biosciences; Will Trade Under Ticker 'NHWK' Effective May 3, 2022
Heat Biologics, Inc. ("Heat") (NYSE American: HTBX), a clinical-stage biopharmaceutical company focused on developing novel biodefense assets and first-in-class therapies to modulate the immune
Benzinga · 04/19 15:01
Heat Biologics Announces Planned Name Change to NightHawk Biosciences, Reflecting Company’s Evolution, Therapeutic Pipeline Expansion, Vertical Integration and New Biodefense Capabilities
Key Corporate Updates Announced Via Livestream Event from Manhattan, Kansas, available for replay at Nighthawkbio.comDURHAM, N.C., April 19, 2022 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. (“Heat”) (NYSE American: HTBX), a clinical-stage biopharmaceutical co...
GlobeNewswire · 04/19 15:00
Kansas lands $650M biomanufacturing plant, 500 high-paying jobs from Scorpion Biological Services
The state of Kansas and a subsidiary of a North Carolina-based public company revealed a plan to build a 500,000-square-foot, commercial-scale biomanufacturing plant. The development team for the $650 million project includes a well-known Kansas City-based...
American City Business Journals · 04/19 04:44
REMINDER: Heat Biologics to Host Planned Investor and Media Livestream Event on Tuesday, April 19th at 10:30 AM ET to Discuss Latest Developments
DURHAM, N.C., April 18, 2022 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. (“Heat”) (NYSE American: HTBX), a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system and novel biodefense assets, remin...
GlobeNewswire · 04/18 20:00
Heat Biologics' Subsidiary Outlines Development of New Commercial/Biodefense Biomanufacturing Facility
Benzinga · 04/18 14:29
Heat Biologics’ unit Scorpion, Kansas state to develop biodefense-focused manufacturing facility
Heat Biologics (NYSE:HTBX) said its unit Scorpion Biological Services, a private developer, the state of Kansas and local and university affiliates will develop a new biodefense-focused large molecule and biologics biomanufacturing
Seekingalpha · 04/18 13:02
Heat Biologics’ Scorpion Subsidiary Announces Planned Development of New Kansas Commercial/Biodefense Biomanufacturing Facility
500,000+ square foot facility to support commercial-scale biomanufacturing Livestreaming ceremony with Governor Laura Kelly Live from Manhattan, Kansas today at 11:00am ET/ 10:00am CT today at DUR...
GlobeNewswire · 04/18 12:30
Heat Biologics Unit Plans New Biomanufacturing Facility in Kansas
MT Newswires · 04/18 11:53
Heat Biologics' Announces Planned Investor And Media Livestream Event To Discuss Latest Developments For April 19
Heat Biologics, Inc. ("Heat") (NYSE American: HTBX), a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system and novel biodefense
Benzinga · 04/14 16:37
Heat Biologics Unveils Enhanced Allogeneic Cell Manufacturing Process
New 3-D process designed to increase yield and improve operating efficiency for rapid and scalable manufacturing of HS-110, gp-96 based cell therapies and other cellular productsDURHAM, N.C., March 25, 2022 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. (“Heat”)...
GlobeNewswire · 03/25 12:00
Heat Biologics Launches New Allogeneic Cell Manufacturing Process
MT Newswires · 03/25 10:12
Webull provides a variety of real-time NHWK stock news. You can receive the latest news about NightHawk through multiple platforms. This information may help you make smarter investment decisions.
About NHWK
Heat Biologics, Inc. is a biopharmaceutical company primarily engaged in the development of immune therapies and vaccines. Its gp96 platform is designed to activate the immune system. This platform has applications in cancer and infectious disease. Its platform leverages gp96’s role as a natural molecular warning system that presents antigens to the immune system. HS-110 (viagenpumatucel-L) is its allogeneic cell line biologic product candidate in a series of immunotherapies designed to stimulate a patient’s T-cells to destroy cancer utilizing its gp96 platform. HS-130 is an allogeneic cell line engineered to express the extracellular domain of OX40 ligand fusion protein (OX40L-Fc), a costimulator of T-cells, with the potential to augment antigen-specific CD4+ T-cell and CD8+ T-cell responses when combined with its gp96 platform. It has also developed a COVID-19 vaccine program under its Zolovax, Inc. subsidiary that utilizes its gp96 platform to secrete SARS-CoV-2 antigens.